Update: clinical features of PML
Dr. David Clifford
United States of America
Disclosure : I have provided the meeting a full set of relationships. The primary ones of importance to this talk are supported consultation with Biogen Idec and Elan. I also have clinical trial support from Biogen Idec.
30 slide(s) – 00:36:12 – English – 2010-06-05
Recognize progressive multifocal leukoencephalopathy (PML).
Understand the risk of this disorder in the setting of natalizumab therapy.
Be aware of diagnostic approaches for PML, and the presentation of this disease when it is associate with natalizumab therapy for MS.
Therapeutic options for PML.